Hemab Therapeutics closed a $157 million financing to advance a portfolio aimed at underserved bleeding disorders, including two programs already in clinical testing. The round, led by Sofinnova Partners with participation from Novo Holdings and crossover investors, will fund a pivotal trial planned next year in Glanzmann thrombasthenia and further development of early‑stage assets. CEO Benny Sorensen described the financing as enabling Hemab to build a focused coagulation company addressing conditions with limited commercial incentives for large incumbents. The company highlighted proof‑of‑mechanism data for its HMB‑002 candidate and plans to accelerate sutacimig toward a pivotal path. Investors view the round as a sign that specialized rare‑disease franchises remain fundable when programs show compelling mechanism‑of‑action and clinical signals.